Cargando…
Serology-Based Model for Personalized Epithelial Ovarian Cancer Risk Evaluation
This study aimed to establish a prognosis-prediction model based on serological indicators in patients with epithelial ovarian cancer (EOC). Patients initially diagnosed as ovarian cancer and surgically treated in Fudan University Shanghai Cancer Center from 2014 to 2018 were consecutively enrolled....
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9029686/ https://www.ncbi.nlm.nih.gov/pubmed/35448194 http://dx.doi.org/10.3390/curroncol29040220 |
_version_ | 1784691941200363520 |
---|---|
author | Yan, Tianqing Ma, Xiaolu Hu, Haoyun Gong, Zhiyun Zheng, Hui Xie, Suhong Guo, Lin Lu, Renquan |
author_facet | Yan, Tianqing Ma, Xiaolu Hu, Haoyun Gong, Zhiyun Zheng, Hui Xie, Suhong Guo, Lin Lu, Renquan |
author_sort | Yan, Tianqing |
collection | PubMed |
description | This study aimed to establish a prognosis-prediction model based on serological indicators in patients with epithelial ovarian cancer (EOC). Patients initially diagnosed as ovarian cancer and surgically treated in Fudan University Shanghai Cancer Center from 2014 to 2018 were consecutively enrolled. Serological indicators preoperatively were collected. A risk model score (RMS) was constructed based on the levels of serological indicators determined by receiver operating characteristic curves. We correlated this RMS with EOC patients’ overall survival (OS). Finally, 635 patients were identified. Pearson’s χ(2) results showed that RMS was significantly related to clinical parameters. Kaplan–Meier analysis demonstrated that an RMS less than 3 correlated with a longer OS (p < 0.0001). Specifically, significant differences were perceived in the survival curves of different subgroups. Multivariate Cox analysis revealed that age (p = 0.015), FIGO stage (p = 0.006), ascites (p = 0.015) and RMS (p = 0.005) were independent risk factors for OS. Moreover, RMS combined with age, FIGO and ascites could better evaluate for patients’ prognosis in DCA analyses. Our novel RMS-guided classification preoperatively identified the prognostic subgroups of patients with EOC and showed higher accuracy than the conventional method, meaning that it could be a useful and economical tool for tailored monitoring and/or therapy. |
format | Online Article Text |
id | pubmed-9029686 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-90296862022-04-23 Serology-Based Model for Personalized Epithelial Ovarian Cancer Risk Evaluation Yan, Tianqing Ma, Xiaolu Hu, Haoyun Gong, Zhiyun Zheng, Hui Xie, Suhong Guo, Lin Lu, Renquan Curr Oncol Article This study aimed to establish a prognosis-prediction model based on serological indicators in patients with epithelial ovarian cancer (EOC). Patients initially diagnosed as ovarian cancer and surgically treated in Fudan University Shanghai Cancer Center from 2014 to 2018 were consecutively enrolled. Serological indicators preoperatively were collected. A risk model score (RMS) was constructed based on the levels of serological indicators determined by receiver operating characteristic curves. We correlated this RMS with EOC patients’ overall survival (OS). Finally, 635 patients were identified. Pearson’s χ(2) results showed that RMS was significantly related to clinical parameters. Kaplan–Meier analysis demonstrated that an RMS less than 3 correlated with a longer OS (p < 0.0001). Specifically, significant differences were perceived in the survival curves of different subgroups. Multivariate Cox analysis revealed that age (p = 0.015), FIGO stage (p = 0.006), ascites (p = 0.015) and RMS (p = 0.005) were independent risk factors for OS. Moreover, RMS combined with age, FIGO and ascites could better evaluate for patients’ prognosis in DCA analyses. Our novel RMS-guided classification preoperatively identified the prognostic subgroups of patients with EOC and showed higher accuracy than the conventional method, meaning that it could be a useful and economical tool for tailored monitoring and/or therapy. MDPI 2022-04-12 /pmc/articles/PMC9029686/ /pubmed/35448194 http://dx.doi.org/10.3390/curroncol29040220 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Yan, Tianqing Ma, Xiaolu Hu, Haoyun Gong, Zhiyun Zheng, Hui Xie, Suhong Guo, Lin Lu, Renquan Serology-Based Model for Personalized Epithelial Ovarian Cancer Risk Evaluation |
title | Serology-Based Model for Personalized Epithelial Ovarian Cancer Risk Evaluation |
title_full | Serology-Based Model for Personalized Epithelial Ovarian Cancer Risk Evaluation |
title_fullStr | Serology-Based Model for Personalized Epithelial Ovarian Cancer Risk Evaluation |
title_full_unstemmed | Serology-Based Model for Personalized Epithelial Ovarian Cancer Risk Evaluation |
title_short | Serology-Based Model for Personalized Epithelial Ovarian Cancer Risk Evaluation |
title_sort | serology-based model for personalized epithelial ovarian cancer risk evaluation |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9029686/ https://www.ncbi.nlm.nih.gov/pubmed/35448194 http://dx.doi.org/10.3390/curroncol29040220 |
work_keys_str_mv | AT yantianqing serologybasedmodelforpersonalizedepithelialovariancancerriskevaluation AT maxiaolu serologybasedmodelforpersonalizedepithelialovariancancerriskevaluation AT huhaoyun serologybasedmodelforpersonalizedepithelialovariancancerriskevaluation AT gongzhiyun serologybasedmodelforpersonalizedepithelialovariancancerriskevaluation AT zhenghui serologybasedmodelforpersonalizedepithelialovariancancerriskevaluation AT xiesuhong serologybasedmodelforpersonalizedepithelialovariancancerriskevaluation AT guolin serologybasedmodelforpersonalizedepithelialovariancancerriskevaluation AT lurenquan serologybasedmodelforpersonalizedepithelialovariancancerriskevaluation |